吲哚胺2,3-双加氧酶(IDO): 癌症免疫疗法的生物学和目标

Title:Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies

Volume: 16 Issue: 9

Author(s): Senthamil R. Selvan, John P. Dowling, William K. Kelly, Jianqing Lin

Affiliation:

关键词: 癌症免疫治疗，联合治疗，吲哚胺2

摘要: Indoleamine 2,3-dioxygenase (IDO) is a heme-containing oxidoreductase that catalyzes the initial and rate-limiting step in the breakdown of non-dietary tryptophan. The biology and immunomodulatory role for IDO is discussed in this review with a focus on its interaction with immune cells and its potential therapeutic target in the clinic. IDO has been revealed to be a central regulator of immune responses in a broad variety of physiological and pathological settings, mostly serving as a multifaceted negative feedback mechanism, to self-regulate immune responses. IDO is considered a therapeutic target in cancer and the use of IDO inhibitors as single agent or in combination with other treatment modalities are under active investigation.

Cite this article as:

Senthamil R. Selvan, John P. Dowling, William K. Kelly, Jianqing Lin , Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies, Current Cancer Drug Targets 2016; 16 (9) . https://dx.doi.org/10.2174/1568009615666151030102250